Guided Biofilm Therapy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The guided biofilm therapy market size was valued at USD 1.04 billion in 2025 and is estimated to grow from USD 1.14 billion in 2026 to reach USD 1.78 billion by 2031, at a CAGR of 9.36% during the forecast period (2026-2031). This report is segmented by Product Type (Guided Biofilm Therapy Kits, and More), Indication (Periodontal Disease, and More), Technique (Airflow Technology, Ultrasonic Scaling, and More), Technology (Air Polishing Systems, and More), End User (Dental Clinics, Hospitals, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Guided Biofilm Therapy Market Trends and Insights

Increasing Adoption of Minimally Invasive Periodontal Care

Patient demand for more comfortable procedures is strengthening the position of minimally invasive periodontal care in the guided biofilm therapy market. Erythritol-based air polishing supports supra- and subgingival biofilm removal across implant maintenance, orthodontic care, and peri-implant applications. A randomized clinical study found comparable pocket-depth outcomes for guided biofilm therapy and conventional instrumentation in Stage III and IV non-surgical periodontal therapy. The defined sequence can reduce uncertainty during hygiene appointments and make recall visits easier to plan. This can support more consistent productivity for dental service organizations and group practices. The clinical workflow, therefore, gives these providers a reason to evaluate the protocol beyond equipment performance alone. It also links the quality of the patient visit to a repeatable sequence, which is useful where practices need to maintain consistent service across several locations. The benefit is not only the selected instrument, but also the ability to use the same order of care in daily preventive and periodontal appointments.

Rising Prevalence of Periodontal Disease and Peri-Implant Conditions

The burden of periodontal disease is increasing the need for structured biofilm management in the guided biofilm therapy market. A 2025 Global Burden of Disease analysis reported that more than 1.07 billion people had severe periodontitis worldwide. It reported South Asia’s age-standardized rate at 17,566.1 cases per 100,000 people, while India and China each had more than 200 million cases. A 2025 AO/AAP review found that a history of periodontitis was associated with an odds ratio of 2.92 for peri-implantitis. The same clinical continuum links periodontal management with implant longevity and repeat maintenance needs. Obesity and type 2 diabetes were also identified as peri-implantitis risk indicators in the review, which widens the group of patients who may require careful supportive care. The relationship does not make every patient a candidate for the same procedure, but it increases the importance of routine assessment and maintenance. This supports a broader need for workflows that can be followed consistently across periodontal and implant-related recall visits.

High Capital Cost and Consumables Dependence

Capital investment is a direct barrier to guided biofilm therapy market adoption, especially for small practices in cost-sensitive regions. A complete workstation includes the platform, air-polishing and pocket-cleaning handpieces, training, certification, and replenishment of powders and tips. Powder and tip orders can recur every 2-4 weeks, creating ongoing operating costs after the initial purchase. In lower-income markets, longer payback periods can deter solo practices and small groups. Some providers instead choose mid-tier glycine-based combination scalers as an entry route, which can fragment protocol use and clinical evidence. Geographic concentration in erythritol and high-purity glycine production also creates an exposure to supply-side price pressure. This risk can be more difficult for clinics to manage than the initial device cost because it appears within the recurring budget for each active treatment schedule. A provider evaluating the protocol must therefore consider both capital spending and the continuing cost of maintaining the required consumable supply.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of Preventive and Supportive Maintenance Dentistry
• Integration of Air Polishing and Ultrasonic Workflows
• Limited Awareness and Uneven Clinician Training

Segment Analysis

Air polishing devices held 42.37% of the guided biofilm therapy market share in 2025. They serve as the main biofilm-removal instrument within the protocol and support frequent demand for powders, nozzles, and tips. GBT kits combine hardware with certification-entry materials, which can simplify the first purchasing decision for new users. These kits are relevant for dental service organizations entering preventive dentistry services. Accessories and consumables give manufacturers a revenue stream that does not depend on hardware replacement timing. Powder and tip replenishment every 2-4 weeks can make utilization more predictable after a platform is installed.

Ultrasonic scaling devices are forecast to grow at a 9.82% CAGR through 2031 within the guided biofilm therapy market. In the protocol, ultrasonic instruments address calculus after disclosure and air polishing have cleared biofilm from the surface. This is a more targeted use than traditional full-arch scaling. NSK introduced the Perio-Mate subgingival air polisher in the United States in February 2025, expanding its periodontal care offering. Purpose-specific tips for implants, periodontal sites, and ceramic-safe surfaces can add to accessory demand. The other category includes compact portable air polishers that can support outreach and mobile dentistry programs in Asia-Pacific and the Middle East. These formats extend the addressable use case beyond fixed dental operatories without changing the central role of air polishing in the protocol. Their relevance remains focused on community programs and mobile settings, while platform devices, consumables, and ultrasonic accessories continue to account for the established commercial structure.

Periodontal disease accounted for 38.56% of the guided biofilm therapy market size in 2025. The segment benefits from long-established supportive periodontal therapy and frequent maintenance appointments. Standalone dental biofilm management includes routine prophylaxis for patients without active periodontal disease. This segment benefits where patients seek professional cleaning more frequently than an annual visit. Orthodontic care is also expanding because adult aligner treatment creates more patients needing biofilm control around fixed and removable appliances. Air polishing can address this need without relying on rotary polishing, where enamel abrasion is a concern.

Peri-implantitis is forecast to grow at a 10.17% CAGR through 2031. An AO/AAP review reported peri-implantitis in 21% of implant patients and peri-implant mucositis in 46% of implant patients. The growing implant-treated population increases the need for maintenance at intervals of 3-6 months. A 2025 consensus report described supportive peri-implant maintenance as central to long-term management. This supports demand for instruments designed for peri-implant surface decontamination. Other uses include peri-mucositis management, pediatric caries prevention, and implant-adjacent tissue care, where evidence for guided biofilm therapy protocols is developing. These uses broaden the clinical setting for biofilm management, but periodontal disease remains the volume base because of its established maintenance pathway. The faster peri-implant segment is therefore additive to routine periodontal care rather than a replacement for the main source of treatment appointments.

Complete Report Scope:

• By Product Type
  • Guided Biofilm Therapy Kits
  • Air Polishing Devices
  • Ultrasonic Scaling Devices
  • Accessories
  • Consumables
  • Others
• By Indication
  • Periodontal Disease
  • Dental Biofilm Management
  • Orthodontic Care
  • Peri-Implantitis
  • Others
• By Technique
  • Airflow Technology
  • Ultrasonic Scaling
  • Rinsing Solutions
  • Others
• By Technology
  • Air Polishing Systems
  • Piezoelectric Ultrasonic Systems
  • Magnetostrictive Ultrasonic Systems
  • Biofilm Disclosure and Visualization Systems
  • Others
• By End User
  • Dental Clinics
  • Hospitals
  • Academic Institutions
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 39.16% of the guided biofilm therapy market share in 2025. The region benefits from high dental spending per person, a mature hygiene profession, and partial preventive-service coverage in Canada and the United States. The United States remains the largest market in the region. In January 2026, the FDA granted 510(k) clearance K253254 for the EMS GBT Machine Airflow Prophylaxis Master. The clearance supports commercial deployment of the next-generation device in the United States. Canada’s provincial dental plans and Mexico’s growing urban private-clinic base add to regional demand. High hygiene capacity also supports procedure volume because hygienists can deliver preventive and maintenance care across a large patient base. The United States clearance gives EMS an important route to deploy its current connected platform, while regional demand continues to rest on preventive coverage and clinical autonomy.

Europe is the second-largest regional guided biofilm therapy market and has the greatest concentration of GBT-certified practices. EMS’s base in Switzerland and its established relationships in Germany, the United Kingdom, France, Italy, and Spain support this position. Germany’s reimbursement rules require systematic subgingival biofilm disruption for pockets of 4 mm or more under the updated periodontal directive. The United Kingdom has a split pattern where NHS practices face fee constraints while private practices compete on patient experience. In the Middle East and Africa, GCC private chains have used certification as part of their service positioning. Saudi Arabia and the United Arab Emirates lead this adoption among premium clinic networks. Europe’s advantage comes from the combination of a mature clinical network, established training, and regulatory attention to supportive periodontal therapy. The mix of public reimbursement in Germany and private patient-experience competition in the United Kingdom gives providers different reasons to adopt the protocol.

Asia-Pacific is forecast to grow at a 13.57% CAGR through 2031. Demand is linked to an expanding implant-treated population, higher middle-class dental spending, and new private clinics in China, India, Japan, South Korea, and Australia. Japan’s biocompatibility requirements for oral-contact powder formulations create a significant entry requirement for suppliers. Once met, these standards can also restrict low-cost powder substitutes. South America is expanding through Brazil and Argentina, where dental service organizations are introducing guided biofilm therapy as a differentiator in urban premium hygiene practices. This creates a path for wider adoption, although lower preventive-care revenue and partial insurance coverage still limit the pace in several developing markets. The region’s growth is driven by different conditions across markets, with Japan shaped by stringent material requirements and China and India shaped by clinic expansion and implant care. These differences mean suppliers need to balance premium clinical positioning with accessible equipment and training offers.

List of Companies Covered in this Report:

• Acteon Group
• A-dec
• BIOLASE
• Brasseler USA
• Carestream Dental
• COLTENE Group
• Dentsply Sirona
• DÜRR DENTAL SE
• EMS Electro Medical Systems
• GC Corporation
• Henry Schein
• Hu-Friedy Mfg
• Kerr
• NSK Ltd.
• Parkell, Inc.
• Planmeca
• Straumann Group
• W&H Dentalwerk Bürmoos GmbH
• Young Innovations, Inc.
• Zhermack S.p.A.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support